Analysis of genes related to hereditary cancers
STRucturation of Transcript Analysis of Genes Involved in Hereditary Cancers in Normandy and Hauts de France
This study is testing a new way to analyze genes linked to hereditary cancers to help identify people at risk and improve their treatment options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Rouen Academic / other |
| Locations | 2 sites (Caen and 1 other locations) |
| Trial ID | NCT06861621 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on improving the molecular diagnosis of hereditary cancers by systematically analyzing both DNA and RNA variants. It aims to enhance the interpretation of genomic variants, which is crucial for identifying individuals at risk and guiding their treatment. The study seeks to establish a reliable process for routine access to these analyses, addressing the current gap in resources that prevents comprehensive testing. By utilizing in silico analysis followed by targeted RNA studies, the research aims to provide a more thorough understanding of the impact of genetic variants on cancer risk.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 who are undergoing oncogenetic consultations and have consented to genetic analysis for major predispositions to breast, ovarian, or digestive cancers.
Not a fit: Patients who are minors, unable to provide informed consent, or under guardianship will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate risk assessments and personalized treatment plans for patients with hereditary cancer predispositions.
How similar studies have performed: While the approach of combining DNA and RNA analysis is innovative, similar studies have shown promise in enhancing genetic interpretation in oncogenetics.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Over 18 years of age * Patients seen in oncogenetic consultations and who have given their informed consent for genetic analysis in the context of a major predisposition to breast, ovarian or digestive cancer. * Person who has read and understood the information note and does not object to taking part in the study * Membership of a social security scheme Exclusion Criteria: * Minors * Persons deprived of their liberty or adults under guardianship or incapable of giving their consent * Failure to obtain informed consent
Where this trial is running
Caen and 1 other locations
- Service Oncogénétique Centre François Baclesse — Caen, France (Recruiting)
- Clinique de génétique médicale Guy Fontaine de l'hopital de Flandre CHRU de Lille — Lille, France (Recruiting)
Study contacts
- Principal investigator: Claude HOUDAYER, Professor — Molecular Genetics Department, UH of Rouen
- Study coordinator: David MALLET, Director
- Email: Secretariat.DRC@chu-rouen.fr
- Phone: +33 2 32 88 82 65
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.